Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...

HealthDay News — In a clinical practice guideline issued by the American Thoracic Society and published in the January issue of the American Journal of Respiratory and Critical Care Medicine, updated ...

In today’s fast-paced world, respiratory issues have become increasingly common, affecting individuals of all ages. Whether it’s due to environmental pollutants, allergens, or chronic conditions like ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

LOS ANGELES -- For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ...